Ann: Pre-Submission package lodged with the US FDA, page-34

The pps half because of the poor accuracy for pneumonia which isn't an issue in 1st world since when we see doctor they will just prescribe antibiotic for suspected LRTI which is an medical issue in itself so rarely do LRTI develop into pneumonia, hence TK said the result were very good because LRTI received 75-80% accuracy despite the 33% disagreement.

When RAP mentioned rapid commercialisation they did enter commercialisation in the 6 months into the COVID-19 pandemic but I expected more interest from Europe telehealth provider by now and some small clinic to sign up as supposedly the doctors do find using ResAppDx very useful, revenue from ED will take the longest to realise.